Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bull Math Biol ; 80(5): 1084-1110, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-28536994

RESUMO

We describe here a simple model for the interaction between leukemic cells and the autologous immune response in chronic phase chronic myelogenous leukemia (CML). This model is a simplified version of the model we proposed in Clapp et al. (Cancer Res 75:4053-4062, 2015). Our simplification is based on the observation that certain key characteristics of the dynamics of CML can be captured with a three-compartment model: two for the leukemic cells (stem cells and mature cells) and one for the immune response. We characterize the existence of steady states and their stability for generic forms of immunosuppressive effects of leukemic cells. We provide a complete co-dimension one bifurcation analysis. Our results show how clinical response to tyrosine kinase inhibitors treatment is compatible with the existence of a stable low disease, treatment-free steady state.


Assuntos
Leucemia Mieloide de Fase Crônica/imunologia , Modelos Imunológicos , Antineoplásicos/uso terapêutico , Autoimunidade , Humanos , Leucemia Mieloide de Fase Crônica/tratamento farmacológico , Conceitos Matemáticos , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Tirosina Quinases/antagonistas & inibidores
2.
J Math Biol ; 75(3): 733-758, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28124077

RESUMO

We propose and analyze a simplified version of a partial differential equation (PDE) model for chronic myeloid leukemia (CML) derived from an agent-based model proposed by Roeder et al. This model describes the proliferation and differentiation of leukemic stem cells in the bone marrow and the effect of the drug Imatinib on these cells. We first simplify the PDE model by noting that most of the dynamics occurs in a subspace of the original 2D state space. Then we determine the dominant eigenvalue of the corresponding linearized system that controls the long-term behavior of solutions. We mathematically show a non-monotonous dependence of the dominant eigenvalue with respect to treatment dose, with the existence of a unique minimal negative eigenvalue. In terms of CML treatment, this shows that there is a unique dose that maximizes the decay rate of the CML tumor load over long time scales. Moreover this unique dose is lower than the dose that maximizes the initial tumor load decay. Numerical simulations of the full model confirm that this phenomenon is not an artifact of the simplification. Therefore, while optimal asymptotic dosage might not be the best one at short time scales, our results raise interesting perspectives in terms of strategies for achieving and improving long-term deep response.


Assuntos
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Modelos Biológicos , Antineoplásicos/uso terapêutico , Humanos , Mesilato de Imatinib/uso terapêutico , Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...